Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keaa340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment from Dr Miyake to α1-blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
Int J Urol
January 2025
Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
Selective embolization can effectively alleviate bleeding symptoms in patients with anorectal hemangioma.
World J Gastrointest Surg
January 2025
Department of Gastroenterology and Hepatology/Medical Engineering Integration Laboratory of Digestive Endoscopy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
In this manuscript, I comment on the article by Pospisilova published in the recent issue of the journal, in which selective embolization was used to treat anorectal hemangioma, a rare disease causing lower gastrointestinal bleeding. Anorectal hemangioma can easily be mistaken; for example, the patient in this case was previously misdiagnosed with ulcerative colitis. Choosing the appropriate tests and understanding the typical manifestations of anorectal hemangioma under colonoscopy, computerized tomography, magnetic resonance imaging and other tests are beneficial for diagnosis.
View Article and Find Full Text PDFComment on "Similar susceptibility to temporary hearing threshold shifts despite different audiograms in harbor porpoises and harbor seals" [J. Acoust. Soc. Am. 155, 396-404 (2024)] (L).
J Acoust Soc Am
January 2025
Department of Biology, University of Aarhus, Aarhus, 8000, Denmark.
Gransier and Kastelein [J. Acoust. Soc.
View Article and Find Full Text PDFRetraction Note: Comment on - Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
Neurosurg Rev
January 2025
Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-77, Tamil Nadu, India.
Flurpiridaz F 18: First Approval.
Am J Cardiovasc Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!